Welcome to our dedicated page for ARGAN SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. SEC filings document the company’s operating results, material events and governance as a NYSE-listed construction services issuer. Recent 8-K filings report quarterly and fiscal financial results, cash dividends, share repurchase program actions, and engineering, procurement and construction contract developments involving Gemma Power Systems and power-generation projects.
Proxy materials cover board elections, executive compensation, equity awards, shareholder voting matters and related governance disclosures. The filings also identify Argan’s common stock registration and formal event reporting for capital allocation and project-backlog developments.
Argan Inc. director Cynthia Flanders reported multiple stock option exercises in Argan Inc. common stock. On January 13, 2026, she exercised four "Option to Purchase Common Stock" awards covering 10,000 shares at $40.15 per share, 10,000 shares at $45.75 per share, 5,000 shares at $37.13 per share, and 5,000 shares at $35.72 per share, each described as using the net settle method.
Following these exercises, her directly held common stock increased in steps to 45,207 shares. The Form 4 also shows that after the transactions she continued to hold derivative positions in options to purchase Argan common stock, including 21,500, 11,500, 6,500 and 1,500 option shares at the respective exercise prices.
Argan Inc. director William F. Leimkuhler reported two open-market sales of the company’s common stock. On January 12, 2026, he sold 2,164 shares at an average price of $318.28 per share, and on January 13, 2026, he sold 4,212 shares at an average price of $320.53 per share, for a total of 6,376 shares sold.
After these transactions, Leimkuhler directly beneficially owned 60,983 shares of Argan common stock. The filing classifies him as a director and indicates the form is filed by one reporting person.
Argan Inc. director Peter W. Getsinger reported multiple stock transactions in early January 2026. On January 7, 2026, he sold 4,000 shares of Argan common stock on the open market at an average price of $328.34 per share. That same day, he exercised a stock option to purchase 7,500 shares at an exercise price of $40.15 per share using the net settle method, resulting in 6,595 shares of common stock being acquired.
On January 8, 2026, Getsinger sold another 6,595 shares on the open market at an average price of $313.71 per share. Following these transactions, he directly owned 7,847 shares of Argan common stock and held 14,000 stock options to purchase additional shares.
Argan Inc. director William F. Leimkuhler reported multiple stock option exercises in the company’s common stock. On January 7, 2026, he exercised options granted between December 2019 and December 2022 to purchase blocks of 10,000 and 5,000 shares at exercise prices of $40.15, $45.75, $37.13, and $35.72 per share, using the net settle method. These exercises increased his directly held common stock, and following the reported transactions he directly owned 67,359 Argan shares.
A holder of AGX common stock has filed a notice under Rule 144 to sell 6,595 shares through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $2,068,918.11. The sale follows an exercise of stock options under a registered plan on 01/07/2026, paid in cash for the same number of shares.
The notice reports 13,873,410 common shares outstanding. It also lists recent sales for the same person over the past three months: 6,493 shares on 10/20/2025 for $1,911,329.25, 2,000 shares on 10/17/2025 for $584,000.00, and 4,000 shares on 01/07/2026 for $1,313,353.88. The seller represents that they are not aware of undisclosed material adverse information about the issuer.
Argan Inc. insider William Leimkuhler has filed a notice of proposed sale of common stock under Rule 144. The filing covers 17,420 shares of Argan Inc. common stock to be sold through Fidelity Brokerage Services on the NYSE, with an aggregate market value of 6,084,000 and an approximate sale date of 01/08/2026.
The shares were acquired on 01/07/2026 through a stock option exercise from the issuer, with the same date listed for payment. The notice also reports that during the past three months, Leimkuhler sold 200 securities of Argan Inc. on 12/23/2025 for gross proceeds of 67,427.47. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Argan Inc.
An affiliated shareholder of AGX filed a notice of proposed sale of 4,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or around 01/07/2026, with trading reported on the NYSE. The filing notes that there were 13,873,410 shares of this class outstanding.
The seller acquired 2,050 shares on 12/15/2015 via an employee stock purchase plan for cash and 1,950 shares on 01/07/2026 through the cash exercise of stock options under a registered plan. In the past three months, the same seller reported sales of 6,493 shares of common stock on 10/20/2025 for gross proceeds of 1,911,329.25 and 2,000 shares on 10/17/2025 for gross proceeds of 584,000.00.
Argan Inc. director William F. Leimkuhler reported several transactions in the company’s common stock on December 23, 2025. As trustee of the Emily K. Leimkuhler Trust, he sold 100 shares at $337.01 per share in an open-market trade. As trustee of the Elizabeth K. Leimkuhler Trust, he sold another 100 shares at $337.93 per share.
On the same date, he also made a bona fide gift of 500 shares of Argan common stock. After these transactions, the filing shows 900 shares held indirectly for each of the two trusts and 41,034 shares held directly.
Argan Inc. director Peter W. Getsinger reported a bona fide gift of 750 shares of the company’s common stock. The transaction took place on December 23, 2025 and is reported on a Form 4 as a code "G" transaction, which indicates a gift. The reported transaction price is $0, consistent with a non-sale transfer.
Following this gift, the reporting person beneficially owns 11,847 shares of Argan Inc. common stock in direct ownership form. This filing simply updates the insider’s reported holdings and does not reflect an open‑market purchase or sale.
William F. Leimkuhler filed a Rule 144 notice to sell 200 shares of Argan, Inc. common stock through Fidelity Brokerage Services LLC on 12/23/2025 on the NYSE, with an aggregate market value of $67,580.00 and 13,873,410 shares outstanding.
The shares to be sold were originally acquired in two open market purchases of 100 shares each on 10/07/2013 and 10/08/2013, both paid in cash. The filing also reports that during the past three months, Leimkuhler sold 11,802 securities of Argan, Inc. on 10/01/2025 for gross proceeds of $3,242,370.73.
By signing the notice, the seller represents that he is not aware of any material adverse, non-public information about Argan, Inc. and that any trading plan or instructions intended to satisfy Rule 10b5-1 were adopted without such undisclosed information.